Status:
COMPLETED
Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborating Sponsors:
Pfizer
Conditions:
Tobacco Dependence
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
The purpose of this study was to find out how varenicline works to help people quit smoking. Varenicline, also known as Chantix™, is an U.S. Food and Drug Administration (FDA) approved medication that...
Detailed Description
We proposed the following primary hypotheses: 1. Tonic (i.e., non-cue-provoked) craving levels would be lower in participants receiving varenicline versus placebo. 2. Cue-provoked cravings (self-repo...
Eligibility Criteria
Inclusion
- 18-60 years of age
- Smoke at least 15 cigarettes daily
- Expired-air carbon monoxide (CO) \> 10 ppm
- Medically eligible to receive Varenicline.
Exclusion
- Patients who are pregnant or lactating
- Who show evidence of renal dysfunction (BUN \> 25 mg/dL, or creatinine \> 1.3 mg/dL)
- Are using other smoking cessation medications
- Have current psychiatric disorders (i.e. major depression, manic depression, and/or psychotic episodes) as determined by the Structured Clinical Interview for DSM Disorders (SCID) (First et al., 1996), will be excluded
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
163 Patients enrolled
Trial Details
Trial ID
NCT00747643
Start Date
September 1 2008
End Date
August 1 2010
Last Update
December 16 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States, 33612